Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.77%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.86 per share when it actually produced earnings of $0.91, delivering a surprise of 5.81%.Over the last four quarters, the company ...

Financial Data and Key Metrics Changes - First quarter EXPAREL sales increased to $136.5 million compared to $132.4 million in 2024, driven by volume growth [34] - First quarter non-GAAP gross margin improved to 81% from 72% year-over-year [35] - Adjusted EBITDA for the first quarter was $44.1 million [35] - The company has $494 million in cash and investments, indicating a strong balance sheet [37] Business Line Data and Key Metrics Changes - ZILRETTA sales declined to $23.3 million from $25.8 million in 2024, attributed to the transition to new sales forces [34] - Ioverao sales slightly increased to $5.1 million from $5 million in the first quarter of 2024 [34] - The transition to new sales teams for ZILRETTA and Ioverao is expected to stabilize and improve sales in the upcoming quarters [35] Market Data and Key Metrics Changes - First quarter average daily EXPAREL sales and volumes were up approximately 7% over 2024 after adjusting for two fewer selling days in 2025 [12] - There was a more than 30% increase in both new and reactivated EXPAREL accounts [12] - The company is seeing encouraging early indicators in the adoption of the "no pain" reimbursement pathway for outpatient surgical procedures [11] Company Strategy and Development Direction - The company introduced a "five by 30" strategy aimed at accelerating growth in its commercial business and advancing its innovative pipeline [6] - The settlement of patent litigation for EXPAREL extends exclusivity to 2039, providing a strong foundation for future growth [10] - The company is focusing on becoming a leader in musculoskeletal pain and exploring partnerships for its HCAD platform [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early signs of growth and the potential for significant cash flow from EXPAREL [10][22] - The company anticipates a more meaningful uptick in sales in the second half of the year as awareness of the "no pain" initiative grows [40] - Management is closely monitoring potential tariff impacts but does not expect material effects on operations [40] Other Important Information - The company announced a $300 million stock repurchase program, reflecting confidence in its growth outlook [21] - The HCAD platform is expected to unlock new gene therapies for common diseases, aligning with the company's strategic objectives [32] Q&A Session Summary Question: What proportion of patients are covered by Medicare and how does "no pain" apply? - The company indicated that over 50% of inpatient procedures are commercially covered, while outpatient settings skew more towards Medicare [49] Question: What needs to be shown for wide adoption of PCRX201? - Management noted that providing a year or more of benefit compared to the current standard of care would be transformative [50] Question: What are the logistical challenges with "no pain" and how is education progressing? - The company is seeing significant growth in adoption in community hospitals and ambulatory surgery centers, with ongoing education efforts for larger institutions [57] Question: How will capital be allocated post-settlement with Fresenius? - The company plans to invest in its base business to capitalize on "no pain," advance its pipeline, and return capital to shareholders through the buyback program [64] Question: Are there any enhancements for EXPAREL to extend its lifecycle? - The company continues to innovate EXPAREL and has recently listed additional patents, but there are no new plans for additional indications [73] Question: What is the outlook on gross margins and pricing? - The elimination of RDF royalties is expected to improve gross margins, and pricing is anticipated to remain stable with GPO contracts coming online [86] Question: What is the current competitive landscape? - Management stated that there is no significant new competition, and there remains ample room for growth in market penetration [91]

Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Pacira Biosciences Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be the question and answer session. Speakers' there the Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other Juris ...

Pacira BioSciences Reports First Quarter 2025 Financial Results FOR IMMEDIATE RELEASE NEWS RELEASE -- Conference call today at 4:30 p.m. ET -- BRISBANE, CA, May 8, 2025 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights See "Non-GAAP Financial Information" below. "We entered 2025 sharply focu ...

Core Viewpoint - Pacira BioSciences, Inc. reported strong financial results for Q1 2025, highlighting its commitment to non-opioid pain therapies and the successful execution of its 5x30 strategy, which aims to enhance its market position and drive growth through innovation and strategic acquisitions [4][6][11]. Financial Highlights - Total revenues for Q1 2025 were $168.9 million, a slight increase from $167.1 million in Q1 2024 [6][11]. - Net product sales included $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°, with EXPAREL showing a growth from $132.4 million in the same quarter last year [6][11]. - Net income was reported at $4.8 million, or $0.10 per share, compared to $9.0 million, or $0.19 per share in Q1 2024 [6][11]. - Adjusted EBITDA for the quarter was $44.1 million, slightly down from $44.6 million in Q1 2024 [6][11]. Recent Business Developments - The company successfully settled U.S. patent litigation for EXPAREL, securing exclusivity until 2039, which is expected to enhance market share and cash flow [7][11]. - The first patient was dosed in a Phase 2 study for PCRX-201, targeting osteoarthritis of the knee, with topline results expected by the end of 2026 [7][11]. - A favorable court ruling eliminated the royalty obligation on EXPAREL sales to RDF, allowing the company to cease future payments and seek repayment for previously paid royalties [7][11]. - The corporate headquarters was relocated to Brisbane, California, aligning with the company's growth strategy [7][11]. Strategic Initiatives - The company reiterated its full-year 2025 financial guidance, projecting total revenues between $725 million and $765 million, with a non-GAAP gross margin of 76% to 78% [21][11]. - Pacira acquired GQ Bio Therapeutics GmbH to enhance its 5x30 growth strategy, bringing in a novel local delivery platform for genetic medicines [11][37]. - The company is focused on expanding the market for EXPAREL and other products through strategic initiatives and clinical trials [11][40].

Core Insights - Pacira BioSciences, Inc. is presenting new data on its gene therapy candidate PCRX-201 at the 2025 EULAR Annual Congress, highlighting its commitment to innovative, non-opioid pain therapies [1] Group 1: Clinical Data and Study Results - The Phase 1 study of PCRX-201 demonstrated that a single intra-articular injection was safe and provided sustained clinical benefits for patients with moderate-to-severe knee osteoarthritis over three years [2] - In a previous Phase 1 study, PCRX-201 showed sustained improvements in knee pain, stiffness, and function for two years post-administration, with a well-tolerated safety profile [3] - PCRX-201 has received RMAT designation from the FDA and ATMP designation from the EMA, marking it as the first gene therapy to achieve these clinical results in knee osteoarthritis [3] Group 2: Ongoing Research and Development - Following promising Phase 1 results, dosing is currently underway in a Phase 2 study (ASCEND study) for the treatment of knee osteoarthritis [4] - The company is advancing the development of PCRX-201 as a novel, locally administered gene therapy aimed at treating prevalent diseases like osteoarthritis [5] Group 3: Company Overview - Pacira BioSciences focuses on delivering innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera® [5] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications, while ZILRETTA is an extended-release injection for osteoarthritis knee pain [5]

Core Insights - The Medical sector is experiencing a robust first-quarter earnings season, with several drugmakers reporting results, and large caps like J&J, Merck, and Amgen exceeding earnings and sales estimates [1][2] - Overall, first-quarter earnings for the Medical sector are projected to rise by 40%, with revenues expected to increase by 8.3% [3] Earnings Performance - As of April 30, 45% of Medical sector companies, representing approximately 57.9% of the sector's market capitalization, have reported earnings, with 66.7% beating both earnings and revenue estimates [2] - Year-over-year earnings growth for the sector is reported at 60.5%, while revenues have increased by 7.8% [2] Company Highlights - **Novo Nordisk**: Expected to report earnings of 92 cents per share and revenues of $11.33 billion, with strong sales anticipated from diabetes and obesity care products [6][7] - **Pacira BioSciences**: Projected earnings of 57 cents per share and revenues of $174.96 million, driven by sales of its pain-management product Exparel [8][9] - **Ultragenyx Pharmaceuticals**: Expected to report a loss of $1.54 per share and revenues of $141.99 million, with growth driven by its lead drug Crysvita [10][11] - **Acadia Pharmaceuticals**: Anticipated earnings of 6 cents per share and revenues of $241.74 million, primarily from sales of Nuplazid for Parkinson's disease psychosis [12][13] - **Denali Therapeutics**: Expected loss of 71 cents per share and revenues of $8.3 million, with updates on pipeline programs anticipated during the earnings report [17][18] Earnings Surprise Potential - The Earnings ESP methodology indicates that stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have a high chance of delivering earnings surprises, with a success rate of up to 70% [4][5]

Core Insights - Pacira BioSciences is set to present findings from its Phase 1 study of PCRX-201, a gene therapy for knee osteoarthritis, at the ASGCT Annual Meeting on May 15, focusing on the impact of neutralizing antibodies on therapy efficacy and safety [1][2] - The company has reported promising Phase 1 results showing sustained improvements in knee pain and function over two years, leading to regulatory designations from the FDA and EMA [4][5] Company Overview - Pacira BioSciences specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera, alongside the development of PCRX-201 [6] - PCRX-201 utilizes a proprietary high-capacity adenovirus vector platform and targets chronic inflammatory processes in knee osteoarthritis, a condition affecting over 14 million individuals in the U.S. [3][4] Upcoming Events - The presentation titled "Understanding the Clinical Immunogenicity of Locally Injected HCAd Vector Provides Insight into Optimizing Dosing Strategy" will be delivered by Dr. MiJeong Kim on May 15 [2] - A symposium on "High-Capacity Adenoviral Vectors: Advancing Gene Therapy Beyond AAV to Deliver Cost-Effective Therapies for Common Diseases" is scheduled for May 16 [3]

Core Insights - PharmaCorp RX Inc. has successfully completed the acquisition of a pre-1954 charter company in Ontario, allowing it to operate pharmacies in the region [1][2] - The acquisition is significant as it enables PharmaCorp to bypass ownership restrictions under the Drug and Pharmacies Regulations Act (Ontario), which limits non-pharmacist owned corporations from operating pharmacies [2] - PharmaCorp currently operates three PharmaChoice bannered pharmacies and plans to continue acquiring more pharmacies under the PharmaChoice Canada brand [3] Company Overview - PharmaCorp operates under the TSX Venture Exchange with the symbol PCRX and is focused on expanding its pharmacy operations in Canada [3] - The company aims to acquire both PharmaChoice Canada branded pharmacies and independently owned non-PharmaChoice Canada bannered pharmacies, integrating them into its operations [3]